The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - Point of view

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 473-475

  De Vries, Marijke ^a   Klop, Boudewijn ^a   Castro Cabezas, Manuel ^a  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Apolipoprotein B; Non fasting triglycerides; Non HDL C

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON FASTING HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NONFASTING TRIGLYCERIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPID;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENETIC HETEROGENEITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DIET RESTRICTION; DYSLIPIDEMIAS; PREDICTIVE VALUE; REPRODUCIBILITY; TIME; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; DYSLIPIDEMIAS; FASTING; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900842153     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.024     Document Type: Article

References (31)

1. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.-R., Wiklund O., et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 Jul, 217(1):3-46.
2. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAm Med Assoc 2007 Jul 18, 298(3):309-316.
3. Eberly L.E., Stamler J., Neaton J.D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003 May 12, 163(9):1077-1083.
4. Mora S., Rifai N., Buring J.E., Ridker P.M. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008 Oct 2, 118(10):993-1001.
5. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAm Med Assoc 2007 Jul 18, 298(3):299-308.
6. Arsenault B.J., Rana J.S., Stroes E.S.G., Després J.-P., Shah P.K., Kastelein J.J.P., et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy. JAm Coll Cardiol 2009 Dec 29, 55(1):35-41.
7. Langsted A., Nordestgaard B.G. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem 2011 Mar, 57(3):482-489.
8. Robinson J.G., Wang S., Jacobson T.A. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol 2012 Nov 15, 110(10):1468-1476.
9. Klop B., Cohn J.S., van Oostrom A.J.H.H.M., van Wijk J.P.H., Birnie E., Castro Cabezas M. Daytime triglyceride variability in men and women with different levels of triglyceridemia. Clin Chim Acta 2011 Nov 20, 412(23-24):2183-2189.
10. Mora S., Rifai N., Buring J.E., Ridker P.M. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009 May, 55(5):888-894.
11. Sidhu D., Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med 2012 Dec 10, 172(22):1707-1710.
12. Do R., Willer C.J., Schmidt E.M., Sengupta S., Gao C., Peloso G.M., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013 Nov, 45(11):1345-1352.
13. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007 Jan 30, 115(4):450-458.
14. Kastelein J.J.P., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008 Jul 10, 117(23):3002-3009.
15. Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., et al. Ameta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011 May, 4(3):337-345.
16. Barter P.J., Ballantyne C.M., Carmena R., Castro Cabezas M., Chapman M.J., Couture P., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. JIntern Med 2006 Mar, 259(3):247-258.
17. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994 Apr, 40(4):586-592.
18. Mora S., Glynn R.J., Boekholdt S.M., Nordestgaard B.G., Kastelein J.J.P., Ridker P.M. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention): an inte. JAm Coll Cardiol 2012 Apr 24, 59(17):1521-1528.
19. Boekholdt S.M., Arsenault B.J., Mora S., Pedersen T.R., LaRosa J.C., Nestel P.J., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAm Med Assoc 2012 Mar 28, 307(12):1302-1309.
20. Langsted A., Freiberg J.J., Nordestgaard B.G. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008 Nov 11, 118(20):2047-2056.
21. Sniderman A., McQueen M., Contois J., Williams K., Furberg C.D. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. JClin Lipidol 2010 Jan, 4(3):152-155.
22. Brunzell J.D. Clinical practice. Hypertriglyceridemia. NEngl J Med 2007 Sep 6, 357(10):1009-1017.
23. Walma E.P., Visseren F.L.J., Jukema J.W., Kastelein J.J.P., Hoes A.W., Stalenhoef A.F.H. The practice guideline "Diagnosis and treatment of familial hypercholesterolaemia" of the Dutch Health Care Insurance Board. Ned Tijdschr Geneeskd 2006 Jan 7, 150(1):18-23.
24. Kolovou G.D., Anagnostopoulou K.K., Kostakou P.M., Bilianou H., Mikhailidis D.P. Primary and secondary hypertriglyceridemia. Curr Drug Targets 2009 Apr, 10(4):336-343.
25. De Graaf J., van der Vleuten G.M., ter Avest E., Dallinga-Thie G.M., Stalenhoef A.F.H. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. JClin Endocrinol Metab 2007 Apr, 92(4):1269-1275.
26. Sniderman A.D. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol 2004 Aug, 15(4):433-438.
27. Ayyobi A.F., McGladdery S.H., McNeely M.J., Austin M.A., Motulsky A.G., Brunzell J.D. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003 Jul 1, 23(7):1289-1294.
28. Brunzell J.D., Albers J.J., Chait A., Grundy S.M., Groszek E., McDonald G.B. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. JLipid Res 1983 Mar, 24(2):147-155.
29. Van Aalst-Cohen E.S., Jansen A.C.M., Tanck M.W.T., Defesche J.C., Trip M.D., Lansberg P.J., et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 2006 Sep, 27(18):2240-2246.
30. Berglund L., Brunzell J.D., Goldberg A.C., Goldberg I.J., Sacks F., Murad M.H., et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. JClin Endocrinol Metab 2012 Sep, 97(9):2969-2989.
31. Veerkamp M.J., de Graaf J., Hendriks J.C.M., Demacker P.N.M., Stalenhoef A.F.H. Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study. Circulation 2004 Jun 22, 109(24):2980-2985.